Description
The Germline BRCA1 & BRCA2 Test is an advanced genetic cancer screening test that analyzes mutations in the BRCA1 gene and BRCA2 gene. These genes are strongly linked to Hereditary Breast and Ovarian Cancer (HBOC) syndrome and play a critical role in DNA repair mechanisms.
Mutations in BRCA1/2 significantly increase the lifetime risk of multiple cancers, including breast cancer, ovarian cancer, prostate cancer, and pancreatic cancer. Germline mutations account for approximately:
- 10–15% of ovarian cancers
- 5–10% of breast cancers
- 3–5% of pancreatic and prostate cancers
This precision oncology test is essential for early cancer detection, risk assessment, and personalized cancer treatment planning. Non-fasting.
Sample Required:
The Germline BRCA1 & BRCA2 test requires a blood sample, collected in an EDTA vacutainer (purple top). The sample must be stored under refrigerated conditions (2–8°C) and transported within 72 hours.
Test Time:
The test results are typically available within 12 days, depending on laboratory processing and sequencing workflow.
Test Normal Range:
The normal result is no pathogenic mutation detected in the BRCA1 or BRCA2 genes.
- Negative/Non-reactive: No clinically significant mutation identified
- Positive: Presence of pathogenic or likely pathogenic variant
- VUS (Variant of Uncertain Significance): Requires further clinical correlation
What is the test?
The Germline BRCA1 & BRCA2 test is a next-generation sequencing (NGS)-based genetic test that detects inherited mutations in BRCA genes. It is widely used in cancer genomics, hereditary cancer screening, and precision medicine to identify individuals at high risk for developing cancer.
This test supports:
- Early cancer detection strategies
- Targeted therapy decisions (e.g., PARP inhibitors)
- Risk-reducing interventions
Test Procedure:
A blood sample is collected and processed using Next-Generation Sequencing (NGS) technology with high-depth coverage (~450x). The DNA is analyzed to identify mutations, deletions, or duplications in BRCA1 and BRCA2 genes. Results are interpreted by molecular genetic experts.
When to take the test?
This test is recommended in the following scenarios:
- Diagnosis of breast or ovarian cancer, especially at a young age
- Strong family history of cancer (breast, ovarian, pancreatic, prostate)
- Known BRCA mutation in the family
- Planning preventive surgeries (e.g., mastectomy, oophorectomy)
- Before initiating targeted cancer therapy
- For clinical trial eligibility and precision oncology programs
Who should take this test?
- Individuals with early-onset breast cancer
- Patients with triple-negative breast cancer
- Families with multiple cancer cases across generations
- Individuals with male breast cancer or prostate cancer
- People seeking genetic counseling and cancer risk assessment
- Individuals planning family screening and reproductive decisions
Precautions for exceptional cases (pregnancy etc.):
Pregnant individuals or those with existing medical conditions should consult their healthcare provider or genetic counselor before testing. Pre-test and post-test genetic counseling is strongly recommended to understand the implications of results, especially for family members.
Indications for Testing
- Breast cancer diagnosis requiring treatment planning
- Strong hereditary cancer risk
- Known familial BRCA mutation
- Prognostic and therapeutic decision-making
- Enrollment in clinical trials
- Family planning and genetic risk counseling
Inheritance Pattern
BRCA1 and BRCA2 mutations follow an autosomal dominant inheritance pattern.
- Each first-degree relative has a 50% chance of inheriting the mutation
- Mutations may be inherited or arise de novo
Why is This Test Important?
The Germline BRCA1 & BRCA2 test enables:
- Early identification of high-risk individuals
- Implementation of preventive strategies (screening, prophylactic surgery)
- Access to targeted therapies (PARP inhibitors)
- Improved survival outcomes and personalized cancer care
Applicable Cancers
- Breast Cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Prostate Cancer
- Pancreatic Cancer
- Uterine & Cervical Cancer
- Testicular Cancer
- Skin Cancer
- Brain Tumors
- Hematologic Malignancies
Technical Information
- Methodology: Next-Generation Sequencing (NGS)
- Depth of Coverage: ~450x (high sensitivity for mutation detection)